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Abstract
Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal
plant extract in gynaecological and breast-cancer treatment.
Methods: Systematic review to evaluate clinical studies and preclinical research on the therapeutic
effectiveness and biological effects of VAE on gynaecological and breast cancer. Search of databases,
reference lists and expert consultations. Criteria-based assessment of methodological study quality.
Results: 19 randomized (RCT), 16 non-randomized (non-RCT) controlled studies, and 11 single-
arm cohort studies were identified that investigated VAE treatment of breast or gynaecological
cancer. They included 2420, 6399 and 1130 patients respectively. 8 RCTs and 8 non-RCTs were
embedded in the same large epidemiological cohort study. 9 RCTs and 13 non-RCTs assessed
survival; 12 reported a statistically significant benefit, the others either a trend or no difference. 3
RCTs and 6 non-RCTs assessed tumour behaviour (remission or time to relapse); 3 reported
statistically significant benefit, the others either a trend, no difference or mixed results. Quality of
life (QoL) and tolerability of chemotherapy, radiotherapy or surgery was assessed in 15 RCTs and
9 non-RCTs. 21 reported a statistically significant positive result, the others either a trend, no
difference, or mixed results. Methodological quality of the studies differed substantially; some had
major limitations, especially RCTs on survival and tumour behaviour had very small sample sizes.
Some recent studies, however, especially on QoL were reasonably well conducted. Single-arm
cohort studies investigated tumour behaviour, QoL, pharmacokinetics and safety of VAE. Tumour
remission was observed after high dosage and local application. VAE application was well tolerated.
34 animal experiments investigated VAE and isolated or recombinant compounds in various breast
and gynaecological cancer models in mice and rats. VAE showed increase of survival and tumour
remission especially in mice, while application in rats as well as application of VAE compounds had
mixed results. In vitro VAE and its compounds have strong cytotoxic effects on cancer cells.
Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research
into clinical efficacy is warranted.
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Background
Breast and gynaecological cancers (i.e. ovarian, endome-
trial, cervical, vaginal, vulval, and fallopian cancers)
account for a significant amount of morbidity and mortal-
ity in women. In Europe an estimated 429,900 cases were
diagnosed as breast cancer in 2006 (13.5% of all cancer
cases) and 131,900 died from it, despite substantially
improved treatment options (surgery, chemotherapy,
radiation, hormonal and targeted therapies) [1]. Of
female cancer survivors more than half had suffered from
breast or gynaecological cancer [2].
40% to 80% of these patients use complementary thera-
pies additionally to well-established treatments [3-8].
This includes a variety of medicinal plants, but also acu-
puncture, psychosocial support, yoga, art therapies and
others. These are supportive measures to control symp-
toms, improve quality of life, boost the immune system,
and possibly prolong life. Sufficient evaluation is often
lacking, however, of the extent to which these therapeutic
goals are achieved, as well as of issues relating to safety
and mode of action. Medicinal plants in particular have a
long history in the treatment of cancer and other condi-
tions connected with tumours, and also play a major role
in the development of new drugs today. Over 60% of cur-
rently used anti-cancer agents originally derive from natu-
ral sources such as plants, marine organisms and micro-
organisms [9].
Across Europe, Viscum album L. extracts (VAE or European
mistletoe, not to be confused with the Phoradendron spe-
cies or "American mistletoe") are among the most com-
mon herbal extracts applied in cancer treatment
[3,7,8,10].  Viscum album is a hemi-parasitic shrub and
contains a variety of biologically active compounds. Mis-
tletoe lectins (ML I, II and III) have been most thoroughly
investigated. MLs consist of two polypeptide chains: a car-
bohydrate-binding B-chain that can bind on cell surface
receptors, which enables the protein to enter the cell [11-
13]; and the catalytic A-chain which can subsequently
inhibit protein synthesis, due to its ribosome-inactivating
properties, by removing an adenine residue from the 28S
RNA of the 60S subunit of the ribosome [11]. Other phar-
macologically relevant VAE compounds are viscotoxins
and other low molecular proteins, VisalbCBA (Viscum
album chitin-binding agglutinin) [14], oligo- and polysac-
charids [15,16], flavonoids [17], vesicles [18], triterpene
acids [19], and others [20,21]. Whole VAE as well as sev-
eral of the compounds are cytotoxic and the MLs in partic-
ular have strong apoptosis-inducing effects [22-24]. MLs
also display cytotoxic effects on multidrug-resistant cancer
cells (e.g. MDR+ colon cancer cells [25]) and enhance
cytotoxicity of anticancer drugs [26,27]. In mononuclear
cells VAE also possess DNA-stabilizing properties. VAE
and its compounds stimulate the immune system (in vivo
and in vitro activation of monocytes/macrophages, granu-
locytes, natural killer (NK) cells, T-cells, dendritic cells,
induction of a variety of cytokines such as IL-1, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12, GM-CSF, TNF-α, IFN-γ (over-
view see [20,21]). The cytotoxicity of human natural and
lymphokine-activated killer cells, for instance, can be
markedly enhanced in vitro by VAE rhamnogalacturonans,
which bridge these killer cells with NK-sensitive or insen-
sitive tumour cells [28,29]. Furthermore, VAE seem to
interfere with tumoural angiogenesis [30,31]. Injected
into tumour-bearing animals, VAE and several of their
compounds (MLs, a 5 kDa protein not specified further,
protein complexes isolated by Vester and colleagues, oli-
gosaccharids) display growth-inhibiting and tumour-
reducing effects [20,21]. Despite extensive experimental
analyses of their biological properties, many questions
regarding the precise mode of action of VAE still remain.
For clinical application VAE are made from mistletoes
grown on different host trees [Host trees of VAE: Fir (Abies,
A); maple (Acer, Ac); almond tree (Amygdalus, Am); birch
(Betula, B); whitethorn (Crataegus, C); ash tree (Fraxinus,
F); appletree (Malus, M); pine (Pinus, P); poplar (Populus,
Po); oak (Quercus, Qu); willow (Salix, S); lime (Tilia, T),
elm (Ulmus, U)], either by aqueous extraction, partly com-
bined with fermentation, or by pressing procedures.
Depending on host tree, harvesting time and extraction
procedure, VAE vary in regard to their active compounds
and biological properties. Different commercial VAE
preparations are available, and a recombinant ML (rML)
drug is currently being developed and tested in clinical tri-
als [32,33].
Clinical effects of VAE in cancer have been investigated in
a variety of studies and assessed in systematic reviews [34-
39]. These reviews, however, had inconsistent results, they
are outdated, incomplete or concentrate on partial
aspects. No review has yet assessed clinical and preclinical
effects specifically and comprehensively for breast and
gynaecological cancer, although there is widespread usage
in these patients [3,7]. Our primary aim was therefore to
assess the potential therapeutic effectiveness of VAE, and
their potential biological effects on breast and gynaeco-
logical cancer in clinical and preclinical studies.
Methods
Design
Systematic review of clinical and preclinical studies inves-
tigating the influence of VAE on breast or gynaecological
cancer.
Search strategy
We used a systematic process to search the following data-
bases for clinical trials – AMED, Biosis Previews, Cochrane
Library (Cochrane Database of Systematic Reviews,Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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Cochrane Controlled Trials Register, The NHS Economic
Evaluation Database, Health Technology Assessment
Database), Embase, Medline/Premedline, NLM Gateway,
private databases – from inception of these databases to
December 2008 using the terms (MISTLETOE OR VIS-
C U M ?  O R  M I S T E L ?  O R  I S C A D O R ?  O R  I S C A R  O R
HELIXOR OR ABNOBA? OR ISCUCIN OR ISOREL OR
VISOREL OR ?SOREL OR WELEDA OR WALA OR
EURIXOR OR LEKTINOL OR PLENOSOL OR AVISCU-
MINE) AND (STUDY? OR STUDIE? OR TRIAL OR EVAL-
UAT? OR RANDOM? OR INVESTIG? OR COHORT? OR
KOHORT? OR OUTCOME?). The reference list from each
potentially eligible study, relevant review article and text-
book was checked, and experts in the field and manufac-
turers of mistletoe preparations were contacted for
additional reports.
Regarding in vitro or in vivo (animal) experiments on anti-
cancer effects, we checked title and abstract, and, where
necessary, the whole article of each VAE-related reference
in the databases (Medline/Pubmed and comprehensive
private databases, using above mentioned terms but with-
out restriction to clinical studies) and in major surveys.
Selection
The following selection criteria were used for inclusion of
studies in the analysis: (I) prospective randomized or
non-randomized controlled clinical trial, or prospective
single-arm cohort study (e.g. phase II trial) or pharmaco-
epidemiological cohort study; (II) study population with
breast or gynaecological cancer, i.e. ovary, uterus, cervix,
genital cancer, or cervical intraepithelial neoplasm (CIN);
(III) intervention group treated with VAE preparation;
(IV) clinically relevant outcome (i.e. survival, disease-free
interval, remission, relapse, QoL, or reduction of side
effects or immune suppression during cytoreductive ther-
apy); (V) completion of study; (VI) published or unpub-
lished. Studies were excluded if they: only measured
toxicity or tolerability (phase I trial), only measured stim-
ulation of immunological parameters, were not con-
ducted on cancer patients, or had a retrospective design
(except pharmaco-epidemiological cohort studies). There
were no restrictions on language.
For  in vitro and animal experiments the criteria were
adapted accordingly; unpublished material was not
included however. In vitro experiments were restricted to
cancer cells originating from human tumours.
Validity assessment and data abstraction
Criteria-based analysis was performed on the selected
clinical studies to assess their methodological quality.
Analyses were performed independently by two reviewers
(GK, HK). There were no major differences in study assess-
ment; disagreements were resolved by discussion. Criteria
for assessing strength of evidence in controlled trials were
adapted from the National Health Service Centre for
Reviews and Dissemination [40] and from criteria for
good methodology as already applied in earlier reviews
on VAE trials [34,36,41]. Quality criteria were adjusted for
cohort studies [36]. Data were abstracted by one reviewer
(GK) and checked by a second reviewer (AG). When nec-
essary, primary authors of the trials were contacted for
additional information.
Regarding animal experiments we extracted data on study
size, animal model, tumour type, tumour transfer, inter-
vention, treatment schedule, outcome, physiological
monitoring, side effects, dose-response, randomization,
control treatment, blinding of outcome assessment, pub-
lication in a peer-reviewed journal, and funding source.
Results
Result of literature search
The literature search identified 306 references describing
potential clinical studies (after deletion of duplicates).
After deleting references only describing studies on
immune modulation or toxicity or tolerability (phase I
trial), or only on cancer sites other than breast or gynaeco-
logical, with retrospective evaluation, without quantifica-
tion of results, or only investigating complex treatment
regimes, or describing studies already published else-
where, 48 potential studies were identified that met the
inclusion criteria. Two trials [42,43], conducted in
Poland, were excluded because of severe validity concerns:
a collaborating scientist questioned the alleged randomi-
zation of treatment allocation, and no information could
be obtained from the authors to clarify this question. One
further RCT (on Lektinol® and breast cancer by Schwiersch
et al.) might have met the inclusion criteria but was
unpublished and unavailable. Thus it was possible to
include 46 studies in this review: 19 RCTs, 16 non-RCTs,
and 11 single-arm cohort studies. Of the 46 studies, 43
were published (4 of these only as an abstract), 1 study
was retrieved as a doctoral dissertation, and 2 were
unpublished reports.
1632 VAE-related references were checked by title, abstract
or whole article, book chapter, or book regarding in vitro
or animal studies. Experiments meeting the inclusion cri-
teria were excluded if they were described in another pub-
lication, were not published in a scientific journal,
scientific book or as a scientific dissertation, were unavail-
able (some dissertations from the 1950s and 60s), or if
they did not present sufficient information.
Characteristics of included clinical studies
Tables 1, 2, 3, 4, 5, and 6 show characteristics of the clin-
ical studies. Settings of the studies were mostly academic
hospitals, large community hospitals, and specializedJournal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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cancer hospitals. The studies were mainly conducted in
Germany, but also in Austria, Switzerland, USA, Serbia,
Russia, Bulgaria, Ukraine, Italy, Egypt, Israel, China,
South Korea. Most studies were conducted in more than
one centre. In 31 of the 32 studies published since 2000,
the funding source was identifiable: three studies had
public funding [44-46], 17 a combination of public and
industry funding, and 11 industry funding alone.
Controlled studies
The 19 RCTs [47-63] (Table 1) encompassed 2420 partic-
ipants, 16 non-RCTs [49-53,59,64-72] (Table 2) encom-
passed over 6399 participants (the sample size of one
control group was not published). Cancer sites studied
were breast (n = 20), uterus (n = 4), ovary (n = 6), cervix
(n = 4), and genital (n = 1). One RCT investigated malig-
nant pleural infusion. 4 studies not only investigated
gynaecological or breast cancer but other cancer types as
well.
Stages ranged from early-detected to advanced disease. 33
studies had two arms, one trial had three, and one four
arms. Endpoints were: survival (22 studies), tumour
remission, recurrence or time to recurrence or metastases
(8 studies), pleurodesis (1 study), QoL or coping with dis-
ease (11 studies), QoL or tolerability of concomitant
chemotherapy, radiotherapy or surgery (13 studies).
Length of follow-up varied from three days in one trial to
– usually – months or years.
All treatment groups received conventional care when
indicated, and most patients had undergone prior surgery.
In 16 studies (9 RCTs and 7 non-RCTs) the combination
of VAE treatment and concurrent chemotherapy, radio-
Table 1: Randomized Controlled Clinical VAE Trials on Breast and Gynaecological Cancer: Quality Assessment
Author, Year Quality Criteria Fulfilled in StudiesI Participants ARII
A) B) C) D) E) F) G) H) I) J) K)
Tröger 2009 [47] + - - (+) + + + + (+) (+) + 95 6%
Büssing 2008 [48] +III -III -III -III (-)III -III (-)III (-)III (-)III (-)III -III 65 No data
Grossarth 2008a [49] + + - (-) + (-) + (+) + + - 76 21%
Grossarth 2008b [49] + + - (-) + + + (+) + + - 52 0%
Grossarth 2007a [50] + + - (-) + (-) + (+) + + - 50 16%
Grossarth 2007b [50] + + - (-) + (-) + (+) + + - 48 17%
Grossarth 2007c [51] + + - (-) + + + (+) + + - 38 0%
Grossarth 2006a [52,53] + + - (-) + (-) + (+) + + - 118 36%
S e m i g l a s o v  2 0 0 6  [ 5 4 ] + - ( + ) ( + ) ++ +++++ 3 5 2 4 %
Auerbach 2005 [55] + - (+) (+) + - + (+) + (+) + 23 30%
Piao 2004 [56] + + - (-) + + + (+) + + + 233 4%
S e m i g l a s o v  2 0 0 4  [ 5 7 ] + - ( + ) ( + ) ++ +++++ 2 7 2 4 %
Borrelli 2001 [58] + - (+) (+) + + (+) + (-) (+) - 30 0%
Grossarth 2001a [59] + + - (-) + + + (-) + + - 34 0%
Grossarth 2001b [59] + + - (-) + (-) + (-) + + - 98 20%
Kim 1999 [60] + - - - (-) - (+) (+) (-) (-) - 30IV 13%
H e i n y  1 9 9 1  [ 6 1 ] + - ( - ) ( - ) +( + ) +( + ) ++- 4 6 1 3 %
Gutsch 1988 [62] + - - (-) + (-) + + (+) + - 692 20%
Lange 1985 [63] + + - (-) + (-) + (+) + + - 68 35%
I A) Protection against selection bias, especially by adequate randomization
B) Minimization of heterogeneity by pre-stratification or matching
C) Protection against observer bias by blinding of patient, care provider, and outcome assessor
D) Protection against performance (treatment) bias by standardization of care protocol, documentation of all co-interventions, blinding of patients 
and care providers
E) Protection against measurement (detection) bias by standardization of outcome assessment
F) Protection against attrition (exclusion) bias, lost patients <10% or by intention-to-treat analysis (including non-adherers as randomized) plus per-
protocol analysis (excluding non-adherers) in combination with sensitivity analysis, and by comparison of prognostic characteristics of lost patients 
and compliers
G) Effect measurement relevant and well described
H) Well-described intervention, patient characteristics, disease (diagnosis, stage, duration), previous therapy
I) Well-described study design
J) Well-described results
K) Data quality assured by ICH-GCP guidelines, especially by monitoring
+ = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, - = not fulfilled
II AR: attrition rate (dropouts, protocol deviations, withdrawals, patients did not receive treatment as allocated).
III Assessment based only on an abstract
IV Discrepancy in patient numbers in two presentations (30 and 33), with corresponding discrepancy of resultsJournal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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therapy or surgery was investigated. 13 of these studies
assessed reduction of side effects from these cytoreductive
therapies. Three trials directly compared VAE treatment
versus chemotherapy treatment or versus radiation and
hormones [60,62,66]. In most studies VAE therapy was
used at least partly in an adjuvant setting after surgery or
radiotherapy.
The commercial VAE applied were Iscador®, Helixor®,
Eurixor® or Lektinol®. VAE dosage mostly followed general
recommendations, starting with low doses and increasing
to an individually still well-tolerated dosage, or treating
according to lectin-content (in 6 trials) or leaving treat-
ment modalities to the physician's discretion, which, it
can likewise be assumed, followed general recommenda-
tions. VAE was injected subcutaneously except in three tri-
als employing intravenous infusion or intrapleural
instillation [48,60,65]. Treatment duration was often not
specified and depended on primary endpoint and related
follow-up, ranging from one single application (in one
trial [65]) to repeated applications over months and years.
Control groups either received no further comparison
treatment (n = 27), additional placebo application (n =
5), doxycycline (n = 1), Lentinan (n = 1) or radiation and
hormones (n = 1). 4 trials had double-blinded treatment
application.
Single-arm studies
11 prospective cohort studies [32,44-46,73-80] (Table 6)
included 1,130 patients. Cancer sites studied were breast (n
= 6), ovary (n = 1), CIN (n = 1), malignant pleural effusion
(n = 2) and malignant ascites (n = 2). 8 studies investigated
several cancer types. Tumour stages were advanced or inop-
erable except in three studies. In most studies patients had
received conventional treatment some time previously.
Directly preceding or concurrent anti-cancer treatment had
been applied in two studies (gemcitabine [44], surgery
[45]). Nine studies assessed tumour remission; seven
Table 2: Non-Randomized Controlled Clinical VAE Studies on Breast and Gynaecological Cancer: Quality Assessment
Author, Year Quality Criteria Fulfilled in StudiesI Participants ARII Design/control for 
confounding
A) B) C) D) E) F) G) H) I) J) K)
Grossarth 2008c [49] (+) + - (-) + + + (+) + + - 200 5% Prospective pair-matching
Grossarth 2008d [49] (+) + - (-) + (-) + (+) + + - 282 27% Prospective pair-matching
Loewe-Mesch 2008 
[64]
- - - (-) + (-) + + (+) + - 82 20% Self-selected treatment 
allocation, no adjustment
Grossarth 2007d [50] (+) + - (-) + (-) + (+) + + - 198 24% Prospective pair-matching
Grossarth 2007e [50] (+) + - (-) + + + (+) + + - 132 6% Prospective pair-matching
Grossarth 2007f [51] (+) + - (-) + + + (+) + + - 212 4% Prospective pair-matching
Grossarth 2007g [51] (+) + - (-) + + + (+) + + - 140 6% Prospective pair-matching
Grossarth 2006b 
[52,53]
(+) + - (-) + (-) + (+) + + - 210 20% Prospective pair-matching
Büssing 2005 [65] (-) - - (-) + + (+) (+) (+) + + 105 7% Comparison of two 
different hospitals. Pair-
matching for analysis
Grossarth 2001c [59] (+) + - (-) + + + - + + - 792 4% Prospective pair-matching
Salzer 1987 [66] (+) - - (-) + - + - - (+) - 155 not shown Alternating treatment 
allocation
Fellmer 1966 [67] - - - (-) + - + + - - - 924 15% Treatment allocation by 
neutral attending physician
Majewski 1963 [68] (+) - - (-) + - + - - - - III not shown (15%)IV Alternating treatment 
allocation
Retrolective pharmaco-epidemiological cohort studies
Beuth 2008 [69] - (+) - - (-) - (+) (-) (+) (+) + 681 V Multivariate adjustment 
only for one main outcome 
("complaints")
Bock 2004 [70] - (+) - - (-) - (+) + (+) (+) + 1442 V Multivariate adjustment
Schumacher 2003 
[71,72]
- (+) - - (-) - (+) + (+) (+) + 689 V Propensity score 
adjustment
I–II Abbreviations as in Table 1.
III Number of study patients not indicated; mistletoe group included 155 patients.
IV Numbers given only for mistletoe group.
V Not applicable for retrolective studies.J
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Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival
Site Stage Intervention 
(evaluable 
patients)
Survival Outcomes Author, year, 
reference
Years (median) Hazard ratio 5-year survival and 
others
P-value 95% CI
Randomized controlled trials
Breast T1a-3, N0, M0 Iscador (38) 14.8 0.65 0.2 0.34–1.25 Grossarth 2006a 
[52,53,135]
None (38) 13.8
IIIA–IIIB Iscador (17) 6.3 0.46 0.13 0.16–1.31 Grossarth 2001a 
[59,135,166]
None (17) 2.3
T1-3, N0-3, M0, local 
recurrence
Surgery, radiationI, 
Helixor (192)
Not applicableII 69.1% 5-year survival 0.048 Gutsch 1988 [62]
Surgery, radiationI, 
CMF (177)
67.7% 5-year survival 0.025
Surgery, radiationI 
(274)
59.7% 5-year survival
Breast, others All stages Iscador (39) 3.5 (mean) 0.04 Grossarth 2001b 
[59]
None (39) 2.5 (mean)
Cervix IVA-B Iscador (19) 1.83 0.46 0.12 0.18–1.21 Grossarth 2007c 
[51]
None (19) 1.92
Uterus IA-C Iscador (30) 6.29 0.36 0.014 0.16–0.82 Grossarth 2008a 
[49]
None (30) 5.17
IVA-B Iscador (26) 1.5 1 0.99 0.46–2.16 Grossarth 2008b 
[49]
None (26) 2.0
Ovary IA–IC Iscador (21) 6.75 0.40 0.058 0.15–1.03 Grossarth 2007a 
[50]J
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None (21) 5.58
IV Iscador (20) 2.75 0.33 0.033 0.12–0.92 Grossarth 2007b 
[50]
None (20) 1.58
Non-randomized controlled studies
Breast T1-3, N0, M0 Iscador (84)III 11.75 0.42 0.0002 0.27–0.68 Grossarth 2006b 
[52,53,135]
None (84) 10.13
Local recurrence, 
N0, M0
Iscador (29)IV 5.17 0.0025 Grossarth 2001b 
[59,135]
None (29) 4.33
T1-4, N>1, M0 Iscador (38)IV 4.04 0.0516 Ø same study
None (38) 3.17
TX, NX, M1 Iscador (53)IV 3.08 0.0056 Ø same study
None (53) 2.17
I–III Iscador, (76) 29% alive 1985, after 
11–14 years
not shown Salzer 1987 [66]
Radiation, hormone 
(79)
24% alive 1985, after 
11–14 years
Cervix IB-IVA Iscador (102)III 7.17 0.41 <0.0001 0.27–0.63 Grossarth 2007f [51]
None (102) 5.92
IV Iscador (66)III 2.33 0.54 0.015 0.32–0.89 Grossarth 2007g 
[51]
None (66) 1.83
I–III Radiation, Iscador 
(81)
83% 5-year survival 0.05 Fellmer 1966 [67]
Radiation (709) 69% 5-year survival
Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival (Continued)J
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Uterus IIIA–IVB Iscador (95)III 2.75 0.61 0.023 0.39–0.93 Grossarth 2008c 
[49]
None (95) 1.67
IA-C Iscador (103)III 8.75 0.41 <0.0001 0.26–0.63 Grossarth 2008d 
[49]
None (103) 6.67
Ovary IA–IC Iscador (75)III 6.83 0.47 0.0002 0.31–0.69 Grossarth 2007d 
[50]
None (75) 5.83
IV Iscador (62)III 1.79 0.62 0.077 0.37–1.05 Grossarth 2007e 
[50]
None (62) 1.17
Genital All stages SurgeryI, radiationI, 
Iscador (155)
Disease-specific 
survival partly 
improved
not shown Majewski 1963 [68]
SurgeryI, radiationI,
(not shown)
Retrolective pharmaco-epidemiological cohort studies
Breast I–III Conventional 
therapy, Iscador 
(710)
0.46 0.038 0.22–0.96 Bock 2004 [70]
Conventional 
therapy (732)
I–IV Conventional 
therapy, Eurixor 
(219)
No difference 
observedV
Schumacher 2003 
[71,72]
Conventional 
therapy (470)
I Co-intervention (i.e. radiation) applied to part of the group
II Not applicable since more than 50% alive at study termination
III Data from complete set of patient pairs reported
IV Data only from patient pairs with strict matching reported
V No difference could be found due to limited observation time (median < 10 months)
CMF: Cyclophosphamide, methotrexate, 5-fluorouracil
P-value, 95% CI (confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group.
Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival (Continued)Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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Table 4: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Tumour Behaviour or Pleurodesis
Site Stage Intervention 
(evaluable patients)
Outcome P-value 95% CI Author, year, 
reference
REMISSION
Randomized controlled trials
Breast, ovary, lung T1–4, N0–3, M0–1 ChemotherapyI, Helixor A 
(115)
Remission rate: no 
difference
Piao 2004 [56]
ChemotherapyI, Lentinan 
(109)
Ovary, others Inoperable Radiation, cisplatin, 
holoxan, Helixor (23)
10% complete remission
48% partial remission
5% progress
Lange 1985 [63]
Radiation, cisplatin, 
holoxan (21)
17% complete remission
48% partial remission
4% progress
Pleural effusionII Advanced Helixor (11) 82% complete remission
9% partial remission
<0.05 III Kim 1999 [60]
Doxycycline, meperidine, 
lidocaine (15)
40% complete remission
27% partial remission
DISEASE-FREE INTERVAL, TIME TO EVENT, RECURRENCE (HAZARD RATIO)
Randomized controlled trials
Breast T1a-3, N0, M0 Iscador (38) Time to local recurrences: 
0.44
lymphatic metastases: 0.27
distant metastases: 0.50
all events (incl.death) 0.65
0.18
0.0048
0.061
0.012
0.14–1.44
0.11–0.67
0.24–1.03
0.47–0.91
Grossarth 2006a 
[52,53]
None (38)
Non-randomized controlled trials
Breast T1–3, N0, M0 Iscador (84) Time to local recurrences: 
0.42
lymphatic metastases: 0.22
distant metastases: 0.36
all event (incl.death) 0.66
0.21–0.83
0.10–0.47
0.21–0.62
0.55–0.79
Grossarth 2006b 
[52,53]
None (84)
Cervix IB-IVA Iscador (102) Time to local recurrences: 
1.42
lymphatic metastases: None
distant metast.:1 in Iscador 
group
all event (incl.death) 0.32
0.61
n.a.
n.a.
<0.0001
0.37–5.39
n.a.
n.a.
0.22–0.48
Grossarth 2007f [51]
None (102)Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
Page 10 of 33
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reported QoL or symptomatic relief. Two studies primarily
investigated the toxicity profile, pharmakokinetics and
potential interactions of either the combination of gemcit-
abine and VAE [44,73] or of rML [32], and secondarily
assessed tumour behaviour. The commercial VAE remedies
were Abnobaviscum®/Viscum fraxini, Iscador, Helixor,
Lektinol or Aviscumine® (rML). VAE were applied subcuta-
neously (n = 6), intratumourally (n = 1), intrapleurally (n
= 2), intraperitoneally (n = 2) or as an intravenous infusion
(n = 1). Dosage depended on the preparation and mode of
application; some treated according to lectin content, oth-
ers started with a low dosage and increased successively, or
started with high dosage and applied it consistently once
weekly. For intrapleural and intraperitoneal (repeated)
application, VAE was diluted in 5 to 15 ml or 100 ml solu-
tion. Treatment duration and follow-up ranged from weeks
to, most commonly, months or years.
Quality assessment
Table 1, 2 and 6 summarize the validity assessment. Meth-
odological quality differed substantially in the reviewed
studies. 19 trials had randomized treatment allocation.
The RCTs were mostly small (median sample size n = 60,
range 23–692), particularly when investigating survival
(median n = 52). Although RCTs investigating QoL were
only slightly larger (median n = 68), they nevertheless
encompass 4 trials that largely met modern standards of
clinical trials and three of them had a sample size above
200. In four of the RCTs the patients and physicians were
blinded; three further RCTs had an active or a placebo
control-treatment. – 16 studies were non-randomized
(median sample size n = 203, range 82–1442), 15 of them
had controlled for confounding by close prospective (in
one case retrospective) pair matching, by alternating treat-
ment allocation and by multivariate analysis or propen-
sity score (though in one study only for the main outcome
parameter [69]). – Assurance of data quality according to
ICH-GCP ("Good Clinical Practice") or GEP ("Good Epi-
demiological Practice") guidelines was reported in 5 RCTs
and 4 non-RCTs. Eight of the RCTs and 8 of the non-RCTs
were embedded in the same large epidemiological cohort
study. Most studies did not present a clear documentation
of co-interventions. Regarding the other quality aspects,
most studies – especially the more recent ones – were rea-
sonably well designed and conducted.
In the single-armed studies, study quality was reasonably
good except in an unpublished report [80] and in an
abstract publication [75] with too little information. Two
studies had applied VAE in combination with or subse-
quent to conventional cancer treatment and one study
had explored CIN, which has high spontaneous remission
rates.
Characteristics of the preclinical studies
The in vitro cytotoxicity of different VAEs as well as iso-
lated or recombinant lectins or their A-chain, viscotoxins,
or other protein fractions were tested with different meth-
ods in a variety of human breast, ovarian, uterine, vulvar
and cervical cancer cells [12,20,22,81-110] (Table 7).
Retrolective pharmaco-epidemiological cohort study
Breast I–III Conventional therapy, 
Helixor (167)
Recurrence, metastases, 
reoperation: no difference
Beuth 2008 [69]
Conventional therapy 
(514)
I–III Conventional therapy, 
Iscador (710)
Recurrence: 0.98
Dist. metast. 0.65
0.947
0.172
0.60–1.62
0.35–1.21
Bock 2004 [70]
Conventional therapy 
(732)
I–IV Conventional therapy, 
Eurixor (219)
Time to relapse: 0.28 0.012 0.10–0.76 Schumacher 2003 
[71,72]
Conventional therapy 
(470)
I Chemotherapy: see table 5
II Plural effusion indicates treatment site (primary cancer site: 4 × breast, 1 × cervix, 23 × lung, 1 × stomach, 1 × unknown primary)
III Side effects in Helixor and doxocycline group: pain in 6 and 14, fever in 3 and 6, burning sensation in 0 and 5 patients respectively; difference 
statistically significant (p < 0.05)
P-value, 95% CI (confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group.
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Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL
Site Stage Interventio
n (evaluable 
patients)
Reduction of side effects of 
chemotherapy, radiation or surgery
QoL (*during chemotherapy, radiation) Author, 
year, 
reference
Outcome P-value Measurement scale and outcome P-value 95% CI
Randomized controlled trials
Breast T1–3, N0–2, M0 CAF, Iscador 
or Helixor 
(59)
Neutropenia 15% 0.195 EORTC QLQ-C30* 
(Pain*, diarrhoea*, role*, insomnia*, nausea/vomiting*)
0.0438 to
0.0003
Tröger 2009 
[47]
CAF (30) 27%
No data (F)EC, 
Iscador M 
(32)
EC-associated inhibition of 
granulocyte function: no 
difference.
Reduction of EC-related side 
effects (nausea, constipation, 
pain, stomatitis).
Lymphocytes, retching, emesis: 
no difference
>0.27 EORTC QLQ-C30*, BR 23*, Rhodes Index*: no 
difference
No data No data Büssing 2008 
[48]
(F)EC (33) "significant"
T1a-3, N0, M0 Iscador (38) Self-regulation questionnaire,
Hazard-ratio
0.35 0.05–0.60 Grossarth 
2006a 
[52,53]
None (38)
T1–3, N0-N+, M0 CMF, 
Lektinol 15 
ng ML (169)
Haematological parameters, hospitalization, 
paracetamol, metoclopramid: no difference.
Leucopenia ↓ (trend)
FACT-G*
↑ 4.4
GLQ-8* sum
↓ 28.9
Spitzer 
uniscale*
↓ 12.2
KPS*
No 
difference
<0.0001 Semiglasov 
2006 [54]
CMF, placebo 
(168)
FACT-G*
↓ 5.11
GLQ-8* sum
↑ 94.8
Spitzer 
uniscale*
↑ 10.8
T1–2, N0–1, M0 CMF, 
radiation, 
Helixor A 
(11)
CMF-induced 
NK-cell 
decrease ↓ SCE-
increase ↓
other immune 
markers: no 
difference
0.005
n.s.
EORTC 
QLQ-C30*
No difference, data not 
shown
not shown Auerbach 
2005 [55]J
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CMF, 
radiation, 
placebo (9)
T1–3, N0-N+, M0 CMF, 
Lektinol 5 ng 
ML (66)
Haematological 
parameters, 
hospitalization, 
paracetamol, 
metoclopramid: 
no difference. 
immune 
markerers: 
CD4, CD4/
CD8, NK-cell-
activity: 
significant ↑
GLQ-8* sum
No 
difference
Spitzer 
uniscale*
No data
QLQ C-30*
No 
difference
<0.05 Semiglasov 
2004 [57]
CMF, 
Lektinol 15 
ng ML (65)
GLQ-8* sum
Superior 
60,8mm
Spitzer 
uniscale*
Superior 
16,4 mm
CMF, 
Lektinol 35 
ng ML (64)
GLQ-8* sum
No 
difference
Spitzer 
uniscale*
No data
CMF, placebo 
(66)
IIIA–IIIB Iscador (17) Self-
regulation 
questionnair
e 
(score 1–6)
2.92 → 3.7 0.13 Grossarth 
2001a [59]
None (17) 2.87 → 2.99
IV Iscador 
spezial (20)
Spitzer score 
questionnair
e
~5 → 7.2 <0.05 Borrelli 2001 
[58]
Placebo (10) ~5.2 → 4.8
Advanced VEC, Eurixor 
(21)
Leukopenia ↓
Platelets: no 
difference
≤ 0.001 QoL index* 
(superior)
Anxienty 
scale* 
(superior)
≤ 0.01 Heiny 1991 
[61]
VEC, placebo 
(19)
Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (Continued)J
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Breast, 
others
All stages Iscador (39) Self-
regulation 
questionnair
e
(score 1–6)
3.41 → 3.87 0.02 Grossarth 
2001b [59]
None (39) 3.85 → 3.62
Breast, ovary, 
lung
T1–4, N0–3, M0–1 Chemothera
pyI, Helixor A 
(115)
Chemotherapy-related adverse 
events
28
not shown FLIC-score*
↑ 9
TCM-score*
↑ -1
KPS* 
increase in % 
of patients
50%
FLIC 0.014
TCM 0.0007
KPS 0.002
Piao 2004 
[56]
Chemothera
pyI, Lentinan 
(109)
Chemotherapy-related adverse 
events
77
FLIC-score*
↑ 4,7
TCM-score*
0
KPS* 
increase in % 
of patients
32%
Ovary IA–IC Iscador (21) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.58 0.0002 0.30–0.90 Grossarth 
2007a [50]
None (21)
Ovary, 
others
Inoperable Radiation, 
cisplatin, 
holoxan, 
Helixor (23)
Nausea ↓,
vomiting ↓,
depression of 
leucopoiesis ↓
0.005, 0.08,
0.003
KPS* 67% → 76% 
(p = 0.0008II)
not shown Lange 1985 
[63]
Radiation, 
cisplatin, 
holoxan (21)
70% → 74% 
(p = 0.12II)
Cervix IVA-B Iscador (19) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.7 0.014 0.15–1.05 Grossarth 
2007c [51]
None (19)
Uterus IA-C Iscador (30) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.4 0.0012 0.15–0.70 Grossarth 
2008a [49]
None (30)
Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (Continued)J
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Non-randomized controlled studies
Breast T1–3, N0, M0 Iscador (84) Self-regulation 
questionnaire
Hazard-ratio
0.20 0.031 0.00–0.35 Grossarth 
2006b 
[52,53]
None (84)
I–II Surgery, 
CMF/EC, 
Iscador (33)
CMF/EC-induced lymphocyte 
decrease ↑,
platelet decrease ↓
n.s,
0.01
EORTC QLQ-C30*, BR 
23*
Reduced 
increase of 
nausea/
vomiting, 
general side 
effects of 
CMF/EC
0.02
0.02
Loewe-
Mesch [64]
Surgery, 
CMF/EC (33)
Breast 
(suspected)
Surgery, 
Iscador M 
spezial (47)
Prevention of surgery-
associated inhibition of 
granulocyte function (PMA- 
and E.coli-stimulated oxidative 
burst)
<0.0001,<0.0
01
Büssing 2005 
[65]
Surgery (51)
Ovary IA–IC Iscador (75) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.30 <0.026 0.10–0.60 Grossarth 
2007d [50]
None (75)
Cervix IB-IVA Iscador (102) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.25 <0.0005 0.15–0.35 Grossarth 
2007f [51]
None (102)
Uterus IA-C Iscador (103) Self-regulation 
questionnaire, (score 1–6) 
median difference
0.65 <0.0005 0.4–0.95 Grossarth 
2008d [49]
None (103)
Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (Continued)J
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Retrolective pharmaco-epidemiological cohort study
Breast I–III Conventional 
therapy, 
Helixor (167)
Odds ratio for occurrence of disease- or treatment 
associated symptoms: 0.508
0.319–0.811 Beuth 2008 
[69]
Conventional 
therapy (514)
I–III Conventional 
therapy, 
Iscador (710)
Adverse drug reactions ↓, 
Odds ratio: 0.47
95% CI 0.32–
0.67
Odds ratio for being symptom-free 3.56 (vomiting, 
headache, exhaustion, depression, concentration, sleep, 
dizziness, irritability) ↑
2.03–6.27 Bock 2004 
[70]
Conventional 
therapy (732)
I–IV Conventional 
therapy, 
Eurixor (219)
Symptom mean score improved (nausea, appetite, 
stomach pain, tiredness, depression, concentration, 
irritability, sleep)
<0.0001 Schumacher 
2003 [71,72]
Conventional 
therapy (470)
I Chemotherapy (referring to the study by Piao et al.) – breast cancer: CAP, CAF (CAP: Cyclophosphamide, doxorubicin, cisplatin; CAF: Cyclophosphamide, doxorubicin, 5-fluorouracil); ovarian 
cancer: CP, IcP (CP: Cyclophosphamide, cisplatin, IcP: Ifosfamid, carboplatin); non-small cell-lung cancer: VP, MViP (VP: Vinorelbine, cisplatin; MViP: Mitomycin, vindesine, cisplatin).
II Statistical significance of pre-post difference within each group
QoL: Quality of life; KPS: Karnofsky Performance Status Scale SCE: Sister chromatid exchange; ↑: increase; ↓: decrease. P-value, 95% CI: Statistical significance of difference between mistletoe (or 
other verum) and control group; n.s.: not statistically significant; EC: Epirubicin, cyclophosphamide (F: 5-fluorouracil); VEC: Vindesine, epirubicin, cyclophosphamide; CMF: Cyclophosphamide, 
methotrexate 5-fluorouracil; CAF: Cyclophosphamide, doxorubicin, 5-fluorouracil.
Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (Continued)J
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Table 6: Single-Arm Cohort Studies (e.g. Phase II Trials) on VAE Treatment in Breast and Gynaecological Cancer
Author, Year TreatmentI SiteII OutcomeIII NIV Quality Criteria FulfilledVI
Preparation Injection 
site
Dosage Escalatin
g dosage
Duration CR PR NC PD QoL L M N O P Q
Breast, Ovary, CIN
Mansky 2008 
[44,73]
Helixor
(& gemcitabine)
sc Up to 250 mg, 
daily
Yes 9 w Breast, 
others
0% 10% 47% 43% 27 (+) + + -V (+) (+)
Schink 2006 [45] Helixor
(& surgery)
sc 3/week, varying 
individually
Yes Up to 2 
years
Breast, 
colon
-- - - âIIIa 4 0++( + ) ( + ) V (+) -
Schöffski 2004 
[32]
Aviscumine iv 10 – 6400 ng/kg, 
2/w
Yes 3–24 w, 
median 6 
w
Ovary, 
breast, 
others
0% 0% 30% 70% 37 + (+) + + + +
Mahfouz 1999 [74] Viscum fraxini sc or it 1 × 45 mg/w No 16–136 w Breast 8% 54% 35% 4% â 2 6( + ) ( + ) +( + ) ++
Mahfouz 1998 [75] Abnobaviscum Fr sc 1 × 45 mg/w No 17 w Breast 0% 44% 33% 22% â 9-( - ) ( + ) - -( + )
Finelli 1998 [76] Lektinol sc 2,5 μl/kg, 2/w No Up to 12 
w
Breast, 
others
-- - - â 8 8 4 +++- ++
Portalupi 1995 
[77]
Iscador M sc 2 × 1 ng MLI/kg 
bw × w
No 16 w CIN I–III 41% 27% 27% 5% 22 + + + + + (+)J
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Malignant effusion
Bar-Sela 2006 [46] Iscador M ip 10 mg No repeatedly Ascites 
(ovary, 
others)
Increase of 
interval between 
two successive 
paracenteses 
from 7 to 12 
days, p = 
0.001IIIb
âIIIc 2 3( + ) ( + ) +( + ) ++
Werner 1999 [78] Abnobaviscum Fr ipl 1 × 75 mg/w No 3–8 w Pleural 
effusion 
(breast, 
others)
88% â 3 2+++- ( + ) ( + )
Stumpf 1994 [79] Helixor A, M or P ipl 100–1000 mg Yes repeatedly Pleural 
effusion 
(breast, 
others)
6 1 % 1 1 % 2 2 % 1 8+++( + ) ++
Friedrichson 1995 
[80]
Helixor A, M ip 100–1000 mg, 2/
w
Yes repeatedly Ascites 
(ovary, 
others)
70% â 12 (+) (-) + - (-) +
I sc: subcutaneous, it: intratumoural, ipl: intrapleural, ip: intraperitoneal; iv: intravenous infusion; bw; body weight; w: week
II CIN: cervical intraepithelial neoplasia. Stage: advanced, except in Portalupi 1995, and partly Schink 2006 and Finelly 1998; plural effusion and ascites indicates treatment site
III CR: complete, PR: partial remission, NC: no change, PD: progredient disease, QoL: quality of life, â: improved, ä impaired
IIIa Especially physical functioning, role, fatigue, appetite
IIIb Median values, comparable abdominal circumference and symptom score or drained fluid before or during each paracentesis respectively
IIIcTrend improvement in symptom score, especially abdominal pain, abdominal pressure, and waking up at night due to shortness of breath
IV N: Number of participants
V Concomitant conventional oncological cytoreductive therapies in some of the patients
VI L Well-described patient characteristic and disease (diagnosis, stage, duration), prognostic factors
M Outcome parameter relevant and well described
N Well-described intervention
O Concomitant therapies well described
P Outcome clearly described, temporal relationship between applied therapy and observed outcome precisely described
Q Selection of patients excluded
+ = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, - = not fulfilled
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Animal studies
43 studies were found. 9 of these were excluded as they
investigated: tumour-bearing eggs [111], pre-incubation
of tumour cells with VAE [112,113], different cancer types
without differentiating the results accordingly [114], or
isolated VAE proteins that were unstable [115]. Of the
remaining 34 experiments [96,111,116-134] (Tables 8
and 9), 28 had been conducted in mice and 6 in rats. 22
experiments had included 788 animals, (5–20 per treat-
ment group), one included 282 VAE-treated animals
(number of control animals were not reported), the other
reports gave no details. 32 experiments investigated breast
tumours (15 of these Ehrlich carcinoma, ECa), one uterus
epithelioma and one ovarian cancer. 28 had used murine
tumour models, 5 were of human origin and 1 an autoch-
thonous model (methylnitrosurea-induced tumourigene-
sis). 24 experiments investigated whole VAE (two of these
VAE-activated macrophages), two investigated isolated
MLs, two rMLs, two investigated other isolated proteins,
and four investigated polysaccharides ("Viscumsäure").
VAE were applied systemically in 17 experiments (subcu-
taneous, intraperitoneal, intratumoural on opposite site,
intramuscular), local at the tumour site in 15 experiments
(intraperitoneal, intratumoural, intramuscular), and
without specification in two studies.
These experiments had been conducted in Germany, Swit-
zerland, Austria, USA, India, Croatia and Serbia. 9 of the
34 experiments reported the funding source, 8 of these
had public funding and one a combination of public and
industry funding. 19 had been published since 1990 and
15 before (1938–1989). 21 were published in peer-
reviewed and 2 in other journals, 6 were published in sci-
entific reference books, 1 as a conference abstract, and 4
in a patent specification. Published information was often
insufficient and sometimes extremely sparse. 6 experi-
ments reported randomized treatment allocation. Regard-
ing the control group, placebo treatment was described in
13 experiments – five of these with identical application
schedule to the verum treatment -, no treatment in 11
experiments, and 9 experiments gave no information.
None of the experiments reported a blinded outcome
assessment (but randomized treatment allocation and
blinded outcome assessment are generally routine prac-
tice).
Outcome
We found substantial heterogeneity of the studies in terms
of intervention, patient characteristics, clinical diagnosis,
measured outcomes, design, methodological quality and
potential positive and negative biases. We therefore
regarded quantification of effect size by combining results
as unreliable and decided on a non-quantitative synthesis
and discussion. A subgroup of studies (2 RCTs, 2 non-
RCTs on breast cancer), with a comparable design (all
originating in the same epidemiological cohort study)
had already been analysed in a quantitative meta-analysis
[135].
Results of controlled clinical studies are shown in Table 3
(survival), Table 4 (tumour behaviour) and Table 5 (QoL
and tolerability of conventional cancer treatment); results
of single-arm studies are shown in Table 6.
Results of the preclinical studies are presented in Tables 7,
8 and 9.
Breast cancer
Clinical studies
Survival (Table 3) was investigated by 4 RCTs and 3 non-
RCTs (one of these is shown with three subgroups in Table
3): Two RCTs reported a statistically significant benefit of
VAE (of these one also included other tumour sites, and
the other suffered from a major attrition rate without pre-
venting bias by an intention-to-treat analysis), and two
RCTs reported a small positive trend. The results of the lat-
ter two RCTs were also combined in an individual patient
data meta-analysis; the result just missed significance
(HR: 0.59, 95% CI: 0.34–1.02, p = 0.057) [135]. Two non-
RCTs had observed a statistically significant benefit, and
one a small positive trend. The results of two non-RCTs
were additionally combined in an individual patient data
meta-analysis, and showed highly significant results (HR:
0.43, 95% CI: 0.34–0.56, p < 0.0005) [135]. Tumour
behaviour (Tables 4 and 6) was investigated by two RCTs,
four non-RCTs and 4 single-arm studies. Four of the con-
trolled studies combined VAE and conventional cancer
treatment. These studies partly reported a benefit regard-
ing disease recurrence and time to disease relapse and
partly no difference; none found a disadvantage. Two sin-
gle-arm studies reported tumour remission in 44–62% of
patients after local application of high dosage VAE.
Another study found no remission after the application of
rML. QoL and the reduction of side effects of chemotherapy,
radiation and surgery (Tables 5 and 6) were assessed by 11
RCTs, 6 non-RCTs and 4 single-arm studies: 19 of these 21
studies reported a benefit, mostly statistically significant,
one study reported no QoL-benefit but a reduction of side
effects, and the smallest of these studies found no differ-
ence. Three major pharmaco-epidemiological studies
investigated patient charts and found reduced disease-
and therapy-associated symptoms in VAE-treated groups.
In preclinical studies (Tables 7, 8, and 9) VAE and VAE com-
pounds showed cytotoxic effects in cancer cells. VAE also
counteracted growth factor-induced proliferation and
migration in breast cancer cells [95]. In mice, VAE inhib-
ited tumour growth in most cases, especially when
applied locally and in high dosage. Survival was pro-
longed in most cases, and numbers of metastases andJournal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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Table 7: In-vitro Studies on Cytotoxicity of VAE in Human Breast or Gynecological Cancer Cells
Tumour cell VAE Result Reference
Breast cancer
MFM-223 Iscador Qu, M, A
Iscador P
ML I
IC50 0.05–0.12 mg/ml
1.89 mg/ml
38 ng/ml
[22]
Iscador M, Qu,
Abnobaviscum Fr
Inhibition of proliferation 0.1–1 mg/ml
0.01–1 mg/ml
[81]
KPL-1 Iscador Qu, M, A
Iscador P
ML I
IC50 0.1–0.3 mg/ml
1.94 mg/ml
141 ng/ml
[22]
Iscador M, Qu,
Abnobaviscum Fr
Inhibition of proliferation 1 mg/ml
0,1–1 mg/ml
[81]
Iscucin® A, M, P, C, Po, T, Qu, S Cytotoxicity 0.1 mg/ml [82]
Iscador M
ML I
No stimulation of cell proliferation 0.05–5 ng ML/ml
0.01–5 ng/ml
[83]
MCF-7 Iscador Qu, M, A
Iscador P
ML I
IC50 0.09–0.12 mg/ml
1.61 mg/ml
410 ng/ml
[22]
Lektinol IC50 >10 ng ML I/ml [84]
Iscador Qu, M, P
(max. 1 or 1.5 mg/ml)
Inhibition of S-phase progression
Induction of apoptosis
[85-87]
Iscador M
Iscador P
ML I
Iscador Qu
IC50
No influence
185 μg/ml
no activity
0.003 μg/ml
0.0015–15 μg/ml
[88,89]
Viscotoxin isoforms 
(A1, A2, A3, B, 1-PS)
Viscotoxin isoform U-PS
GI50
LC50
0.02–0.8 μg/ml
0.6 to >1 μg/ml
no activity
[90]
ML I A chain Inhibition of proliferation 0.5 μg/ml [91]
ML I, ML II, ML III Inhibition of proliferation 1–10 ng/ml [91]
TNF & ML I (100 ng/ml) Potentiation of TNF-cytotoxicity [92]
Lektinol IC50 0.003 μg/ml [93]
Helixor P
ML I
IC50 > 150 μg/ml
0.086 μg/ml
[94]
Iscucin M, P, C, Po, T, Qu, S
Iscucin A, Pi
Cytotoxicity 0.1 mg/ml
no activity
[82]
MCF-7/ADR Lektinol IC50 (SRB assay) 0.3 E-4 μg/ml [93]
MAXF 401NL Helixor P
ML I
IC50 0.66 μg/ml
0.003 μg/ml
[94]
Iscador M
Iscador P
ML I
Iscador Qu
IC50
>70% growth inhibition
< 3 μg/ml
no activity
0.353 E-4 μg/ml
10 μg/ml
[88,89]
MAXF 401 Lektinol IC50 < 0.1 E-4 μg/ml [93]Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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MAXF 1162 Lektinol IC50 < 0.1 E-4 μg/ml [93]
MAXF 449 Lektinol IC50 0.2 E-4 μg/ml [93]
MAXF MX1 Lektinol IC50 < 0.1 E-4 μg/ml [93]
MDA-MB-231 Lektinol IC50 0.7 E-4 μg/ml [93]
Helixor P
ML I
IC50 135 μg/ml
0.041 μg/ml
[94]
MDA-MB-468 Helixor P
ML 1
IC50 47 μg/ml
0.006 μg/ml
[94]
MDA-MB-486-HER2 Iscador M Inhibition of epidermal growth 
factor-induced proliferation
0.5 μg/ml [95]
Colo-824 Iscador M
ML I
No stimulation of cell proliferation 0.05–5 ng ML/ml
0.01–5 ng/ml
[83]
HCC-1937 Iscador Qu, M, A
Iscador P
ML I
IC50 0.1 to 0.3 mg/ml
2.14 mg/ml
320 ng/ml
[22]
Iscucin A, M, P, C, Po, T, Qu, S Cytotoxicity 0.1 mg/ml [82]
BT474 Helixor M, A Cytotoxicity (WST-1) Maximum (80 and 100%) with 25 
mg/ml
[96]
Primary breast cancer Iscador M, Qu
Abnobaviscum Fr
Mitochondrial activity (MTT) 50–80% with 0.1–0.001 mg/ml [81]
Abnobaviscum M Inhibition of proliferation 0.5–50 μg/ml [97]
ML I Inhibition of proliferation 1–50 ng/ml [20,98]
T47D ML I, II, III IC50 > 0.1 – 1 ng/ml [99]
ML I A-chain Inhibition of proliferation 10 ng/ml [91]
BT549 ML I A-chain Inhibition of proliferation 500 ng/ml [91]
HBL100 ML I A-chain Inhibition of proliferation 100 ng/ml [91]
Breast cancer cells ML II, ML III, viscotoxins Cytotoxicity [100]
Ovarian cancer
OVXF 1619L Helixor P
ML I
IC50 119 μg/ml
0.100 E-3 μg/ml
[94]
OVXF 899L Helixor P
ML I
IC50 >150 μg/ml
0.229 μg/ml
[94]
SKOV-3 (HER-2 expression) Recombinant ML I IC50
Induction of apoptosis
0.033 ng/ml [101]
OVCAR3 Iscador Qu, M
(max. 1 or 1.5 mg/ml)
Inhibition of S-phase progression,
Induction of apoptosis
No clear effect [87]
OVXF 899 Lektinol IC50 0.3 E-3 μg/ml [93]
OVXF 1353 Lektinol IC50 0.01 μg/ml [93]
OVXF 1023 Lektinol IC50 < 0.1 E-4 μg/ml [93]
SKOV3 Lektinol IC50 < 0.1 E-4 μg/ml [93]
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Primary ovarian cancer Abnobaviscum M Inhibition of proliferation 5 μg/ml [97]
Uterine cancer
UXF 1138L Iscador M
Iscador P
ML I
Iscador Qu
IC50
Growth inhibition >30%
6.8 μg/ml
No activity
0.16 E-4 μg/ml
15 μg/ml
[88,89]
UCL SK-UT-1B Helixor P
ML I
IC50 > 150 μg/ml
0.038 μg/ml
[94]
SK-UT-1B Lektinol IC50 0.6–5.5 ng ML I/ml [84]
ML I Inhibition of proliferation 0.5–500 ng/ml [98,102]
Iscador M
ML I
No stimulation of cell proliferation 0.05–5 ng ML/ml
0.01–5 ng/ml
[83]
SK-UT-1 ML I Inhibition of proliferation 0.5–500 ng/ml [98,102]
MES-SA ML I Inhibition of proliferation 0.5–500 ng/ml [98,102]
Primary uterus cancer Abnobaviscum M Inhibition of proliferation 5–50 μg/ml [97]
Vulvar cancer
SK-MLS-1 Lektinol IC50 2 to >5 ng ML I/ml [84]
ML I Inhibition of proliferation: 0.5–500 ng/ml [98,102]
Iscador M
ML I
No stimulation of cell proliferation 0.05–5 ng ML/ml
0.01–5 ng/ml
[83]
Cervical cancer
HeLa TNF & ML I (100 ng/ml) Potentiation of TNF-cytotoxicity [92]
ML I Inhibition of protein synthesis 100 μg/ml [12,103]
Protein fractions Complete inhibition of DNA-, 
RNA-synthesis
Proliferation
1 μg/ml
no effect
[104]
Viscotoxins IC50 0.2–1.7 μg/ml [105]
Helixor M Growth inhibition ≥ 0.01 mg/ml [106]
Isorel® Cytotoxicity 30 μg/μl [107]
Isorel A, M, P,
ML I
Cytotoxicity > 1 μl/ml
> 1 μg/ml
[108]
Iscador M
Helixor M
VAE M
LC50 16 μg/ml
35,4 μg/ml
3,9 μg/ml
[109,110]
Iscador M, Qu
Abnobaviscum Fr
Growth inhibition 0.1–1 mg/ml
0.01 mg/ml
[81]
GI50: 50% growth inhibitory concentration
LC50: 50% lethal concentration
IC50: 50% inhibitory concentration
MCF-7/ADR: adriamycin(doxorubicin)-resistant MCF-7 cell line
HER: human epidermal growth factor receptor
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Table 8: Animal Studies of VAE on Breast or Gynaecological Cancer (transplanted human or murine tumours or primary 
autochthonous tumour)
Tumour, site Animal VAE, application and 
dosage
Tumour 
growth
T/C
Survival
ILS
Other outcomes Reference
Human breast Mice
MAXF 449, sc Nude mice Local Abnobaviscum Qu 8 or 4 
or 2 mg/kg, it, qd * 3
6 to 20% [116]
Systemic Abnobaviscum Qu 8 
mg/kg, it, qd * 3
78%
MAXF 449, sc Nude mice Abnobaviscum M 8 mg/kg, sc, 
qd * 3 * 2 w
68% [116]
BT474, sc Mice (BALB/c) Helixor M or A 5 mg, it, qd * 3 
* 2 w
29 to 52% [96]
Murine breast
Carcinoma, sc, iv Mice (CBA/HZgr) Isorel M, 3 mg, sc, qod * 21 No difference Lung-metastases: VAE 
vs. control: 13.4 vs. 37.5
[117]
Carcinoma, sc Mice (CBA/HZgr) Isorel M, 1400 mg/kg, 2 w 20% [118]
Carcinoma, sc Mice (CBA/HZgr) Isorel M, 140 mg/kg Recurrence after 
resection, VAE vs. 
control: 47% vs. 78%
[118]
Carcinoma, iv Mice (CBA/HZgr) Isorel M, 140 mg/kg, ip 52 lung-metastases [118]
Endoxan, 50 mg/kg 23 lung-metastases
Isorel M, 140 mg/kg & Endoxan 
50 mg/kg
10 lung-metastases
Control 76 lung-metastases
C3H adenocarcinoma, 
16/C
Mice (B6C3F1) Iscador M, 50 or 100 mg/kg, ip, 
qd, day 1–14
28% 15 to 20% [119]
RC adenocarcinoma, sc Mice (DBA) VAE I, sc 20 to 40% [111]
ECa, ip Mice (NMRI) VAE (supracritical CO2 
extraction), 2 mL/kg, ip, qd, 
starting day -7, day 0, or day 7
65 to 100%II [120]
ECa, ip Mice (BALB/c) Iscador, 15 μg, ip, day -1 108% [121]
Sodium caseinate & Iscador, 15 
μg, ip, day -1
no death
Sodium caseinate, day -1 0%
ECa, ip Mice (BALB/c) Iscador, 15 μg, ip, day 6 82% [121]
Sodium caseinate, day 6 7%
ECa, ip Mice (BALB/c) Iscador-activated 
macrophages, ip, day 6
49% [121]Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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Non-activated macrophages, 
ip, day 6
4%
ECa, ip Mice (BALB/c) Iscador activated macrophages, 
ip, day 6, 10, 14
98% [121]
Non-activated macrophages, 
ip, day 6, 10, 14
9%
ECa, sc Mice (BALB/c) Iscador, 15 μg, it, day 7 Severe necrosis, 
infiltration of 
lymphocytes and 
macrophages
[122]
ECa, sc Mice (Swiss) Iscador M, 1.66 mg, im, qod * 5 
or 10
3 to 10% [123]
ECa, ip Mice (Swiss) Iscador M, 1.66 mg, ip, qod * 
10
76% [123]
ECa, ip Mice (Swiss) Iscador M, 25 or 50 mg/kg, ip, 
qd * 14
69 to 97% No tumour-free mice [119]
ECa, ip Mice (Swiss) Iscador M, sc, cumulative dose 
4, 5, 150, or 200 mg
-4 to 0% [124]
ECa, sc Mice VAE, it, 0.1–0.2 ccm, qod * 6–
10
Complete remission & 
no recurrence: 27%
[125,126]
Murine breast Rats
Walker carcinosarcoma 
256; sc
Rats (Sprague 
Dawley)
Iscador M, sc, cumulative dose 
11, 16, 500, or 750 mg or 
combination of Iscador M, sc, 
cumulative dose 11 or 500 mg 
& Cetraria praeparata, 
cumulative dose 3 or 164 mg
93 to 115% -16 to 8% [124]
Dunning DMBA-5A; sc Rats Iscador M, 2.5–15 mg, ip, qd No difference Less tumour viability [127]
Walker carcinosarkoma 
256
Rats Iscador M, 0.005–0.5 mg, im, 
qd
No difference Metastases: no 
difference
[128]
Autochthonous
Methylnitrosurea-
induced
Rats (Sprague 
Dawley)
Iscador M c. Arg., sc, 0,2 ml/
day, 50 mg/week * 6 weeks
75% -16% [124]
sc: subcutaneous; im: intramuscular; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week;
qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span
All experiments did have control groups, but these were only mentioned if necessary for results
I Part of a screening programme for substances with anticancer activity (1,000 plant extracts from 107 plant species)
II Relating to volume of ascites; effects greatest with therapy started on day -7
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Table 9: Animal Studies of VAE Compounds in Breast or Gynaecological Cancer (transplanted human or murine tumours)
Tumour, site Animal VAE Tumour growth
T/C (%)
Survival Other outcomes Reference
Human breast tumour
Breast Mice rML 0,3 ng/kg – 3 μg/
kg, ip, qd * 5 * 2–4 w
No effect [129]
Murine breast tumour in mice
C3L5, 
adenocarcinoma; sc
Mice (C3H7HeJ) ML I, 1 ng/kg, sc, q3d, 
day 7–19
160 27.6 lung-metastases [130]
IL-2, twice 6 × 104 
IU/mouse, ip q8h 2 * 
qd * 5
43 2.3 lung-metastases
Combination of ML 1 
& IL-2
37 2.3 lung-metastases
Control 7.5 lung-metastases
ECa, ip Mice (ICR) ML I, 80 ng, ip, day 1 70% died after 50 
days
[131]
A-chain of ML I, 100 
μg, ip, day 1
80% died after 57 
days
B-chain of ML I, 10 
μg, ip, day 1
80% died after 58 
days
Control 100% died after 20 
days
ECa, sc Mice (BALB/c) VAE 5 kDa peptides, 
2 μg, it, day 7
Severe necrosis, 
infiltration of 
lymphocytes and 
macrophages
[122]
ECa, ip Mice (CD-1) Vester' Proteins, ip, 
0.1 or 1 or 10 μ/kg, 
qd * 10
ILS: 0, 33, and -33%I [132]
ECa Mice Polysaccharide 
(„Viscumsäure“), ip, 
qd * 6
Slight effect [133]
Adenocarcinoma 
EO 771
Mice Polysaccharide 
(„Viscumsäure“), ip, 
qd * 6
Moderate effect [133]
Murine breast tumour in rats
Walker 
Carcinosarcoma
Rats Polysaccharide 
(„Viscumsäure“), ip, 
qd * 6
Moderate effect [133]Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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local recurrences were reduced after application of VAE or
of VAE-activated macrophages; one study found no bene-
fit. All experiments using local VAE application found a
benefit in relation to survival and tumour-growth inhibi-
tion. In rats, no clear benefit of VAE could be seen. Results
from applying isolated or recombinant VAE compounds
were inconsistent: some moderate effects of proteins (e.g.
lectins) or polysaccharides were observed in relation to
survival and tumour growth, while others observed none
or possibly also adverse outcomes.
Cervical cancer
Clinical studies: Survival (Table 3) was investigated by one
RCT and three non-RCTs: all four reported a beneficial
outcome which, however, was statistically significant only
in the non-RCTs. Tumour behaviour (Table 4) was investi-
gated by one non-RCT, which could not find an effect on
disease recurrence or metastases mainly because these
events scarcely occurred. One single-arm study reported
41% complete and 27% partial remissions in CIN after
VAE application. QoL (Table 5) was assessed in one RCT
and one non-RCT; both reported a statistically significant
benefit.
Regarding preclinical studies (Table 7), only HeLa cells were
investigated; here VAE and protein fractions showed cyto-
toxic effects.
Uterus cancer
Clinical studies: Survival (Table 3) was investigated by two
RCTs and two non-RCTs; three reported a statistically sig-
nificant benefit while one found no difference. QoL (Table
5) was assessed by one RCT and one non-RCT; both found
a statistically highly significant benefit.
Regarding preclinical studies (Tables 7 and 9), VAE and iso-
lated ML I showed cytotoxic effects in different human
uterus cancer cells. Concerning animal experiments, a pat-
ent specification mentions "moderate" effects of mistletoe
polysaccharides on tumour growth in uterusepithelioma.
Ovarian cancer
Clinical studies: Two RCTs and two non-RCTs investigated
the influence of VAE on survival (Table 3) and reported a
benefit, one of each with statistical significance. Tumour
behaviour (Table 4) was investigated by two RCTs, each
combining VAE and chemotherapy (plus radiotherapy in
one study): these reported comparable outcomes. The
influence of VAE on QoL and tolerability of chemotherapy
and radiation (Table 5) was investigated by three RCTs and
one non-RCT; all of them reported a statistically signifi-
cant positive effect. In one trial using an aggressive chem-
otherapy protocol, higher dosages of Cisplatin and
Holoxan could be given in the VAE group as the side
effects were less intense [63]. One single-arm study
applied recombinant lectins in ovarian cancer but found
no remission.
Regarding preclinical studies (Tables 7 and 9), VAE showed
cytotoxic effects in various ovarian cancer cells. In SCID
mice, rMLs led to increased survival and to more tumour-
free animals at the highest and lowest dosage, while no
effect was observed at the medium dosage.
Genital cancer
Clinical studies: One non-RCT (published in 1963)
reported partly improved disease-specific survival (Table
3). Regarding preclinical studies (Table 7), VAE showed
cytotoxic effects in vulvar cancer cells.
Other gynaecological tumour
Ovary, SoTü 3, ip Mice (SCID) rML 30 ng/kg, ip, qd * 
5 * 12
35% mice alive at 
day 84
40% tumour-free mice 
at day 84
[134]
rML 150 ng/kg, ip, qd 
* 5 * 12
10% mice alive at 
day 84
10% tumour-free mice 
at day 84
rML 500 ng/kg, ip, qd 
* 5 * 12
75% mice alive at 
day 84
65% tumour-free mice 
at day 84
Control 15 mice alive at day 
84
10% tumour-free mice 
at day 84
Uterusepithelioma 
T-8 Guérin
Rats Polysaccharide 
("Viscumsäure"), ip, 
qd * 6
Moderate effect [133]
All experiments did have control groups, but these were only mentioned if necessary for results.
sc: subcutaneous; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week;
qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span.
I Application of 10 μg/kg of proteins had toxic effects
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Malignant effusion
Clinical studies: One RCT and four single-arm studies
investigated treatment of malignant pleural effusion and
ascites (originating from breast or ovarian cancer, among
other cancer sites), and all reported substantial remission
rates (Tables 4 and 6).
Safety
Tolerability was generally good. One case of urticaria and
angioedema [56] and one case of "generalized reaction"
[69] were described. Otherwise no major side effects or
toxicity were reported. Frequent minor, dose-dependent
and spontaneously subsiding symptoms included reac-
tions at the injection site (swelling, induration, erythema,
pruritus, local pain) and mild flu-like symptoms or fever.
In one study, local reactions intensified during concomi-
tant chemotherapy [64]. A higher prevalence of depres-
sion was documented in the unadjusted data of a
retrolective non-RCT [69] in VAE-treated patients; these
patients also had a higher prevalence of other treatments
such as hormones. After intrapleural instillation, VAE
induced significantly fewer side effects than doxycycline
[60]. No indication for an interaction of VAE and chemo-
therapy could be found (i.e. remission rate) and VAE had
no influence on the plasma concentration of gemcitabine
[44,73]. No toxicity was observed in animal studies,
except after application of high doses of an isolated pro-
tein complex with unknown constituents [132].
Discussion
A variety of clinical studies and experiments have investi-
gated the potential therapeutic effects of VAE and its com-
pounds in breast and gynecological cancer, and
predominantly reported positive effects. Nevertheless they
have to be interpreted with caution and within their con-
text.
The strongest and most consistent results from VAE in
clinical studies concern QoL and improved tolerability of
conventional treatment. QoL questionnaires included
mostly well established and validated QoL instruments
and one on psychosomatic self-regulation. The latter is a
16 item QoL instrument that measures competence and
autonomy, in terms of the ability to actively adapt to
stressful life situations and to restore well-being. [136]
This tool has so far been exclusively used in studies focus-
ing on complementary cancer treatments. Improvement
was seen especially in relation to self-regulation, fatigue,
sleep, nausea/vomiting, appetite, diarrhoea, energy, abil-
ity to work, enjoyment of life, depression, anxiety, pain,
and general physical, emotional, and functional well-
being (for more details see Kienle GS, Kiene H: Influence
of mistletoe treatment on quality of life in cancer patients.
A systematic review of controlled clinical studies. Submit-
ted). Regarding the side effects of conventional oncology
treatments, reduced hematopoetic damage (i.e. leukope-
nia) and immuno-suppression was reported by some, but
not by all studies. Similar, less chemotherapy-related
events were observed in some but not in all studies. Valid-
ity of this evidence is quite good. 15 RCTs are available,
four of them double-blinded (three of them showing a
positive result) and one with an active control treatment.
5 RCTs reported following ICH-GCP guidelines and three
of them comprised more than 200 patients each. Ques-
tions remain regarding observation or reporting bias,
which is of major importance in relation to subjectively
assessed outcomes such as QoL and subjective symptoms.
Treatment should therefore be blinded; but blinded sub-
cutaneous VAE application can easily be correctly identi-
fied by doctors and patients [55,137], due to its local
reactions and mild flu-like symptoms. In the four blinded
trials reviewed here, a considerable degree of unblinding
was detected by asking patients and physicians in one
study [55]; and can be presumed in two other of these tri-
als where substantially more VAE-treated patients
reported local reactions than control patients [54,57].
Other RCTs did not blind treatment application, as blind-
ing is unreliable. Therefore questions will remain in
"blinded" as well as in open trials even though in general
cancer or non-cancer trials could not detect relevant
improvements of QoL or disease symptoms due to sugges-
tive administration of inert substances [138-140]. Never-
theless, the frequency, magnitude, duration and
conditions of QoL or symptomatic improvement in the
course of VAE treatment should be clarified in more
detail. Especially relevant might be the further elucidation
of possible effects on cancer-related fatigue (see also
[141]), which is one of the most disabling conditions in
cancer patients, with only few therapeutic options for
influencing it effectively [142-144]. Regarding simple pre-
post assessments of QoL in single-arm studies, it is prob-
ably unnecessary to state that they are generally not appro-
priate for judging influences on QoL, since it is affected by
many factors.
Concerning survival (Table 3), some of the RCTs show a
statistically significant benefit while others show a statisti-
cal trend or no difference. Most of the non-RCTs (which
included larger patient numbers) show a major impact.
The validity of the studies is limited because of their small
sample size (median only 52 participants per RCT), and
because 8 of the 9 RCTs were imbedded in the same
(large) epidemiological cohort study. This study was
started in the 1970s, before modern standards of data
quality control (ICH-GCP, GEP) were established, and it
therefore does not fulfil modern standards in this respect.
The 9th RCT had enrolled more patients but was con-
ducted even earlier, and suffers from a major attrition rate
due to protocol violation [62]; the subsequent analysis
followed the "as treated" instead of the "intention-to-
treat" principle [145]. Hence bias cannot be excluded.
None of the survival studies was blinded, but survival isJournal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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generally not easily affected by observer bias or suggestive
effects [138-140]. Seen altogether, although results were
consistent, questions regarding survival remain and valid-
ity of evidence is moderate at best. An independent, GCP-
conform trial with sufficient power would be desirable to
further evaluate potential survival benefit.
Regarding tumour behaviour, evidence from RCTs is scanty;
most benefits were shown in non-randomized studies. In
single-arm studies of patients with no concomitant con-
ventional cancer treatment, high-dose or local application
of whole VAE led to substantial remission of tumour or
malignant effusion. This was also observed in animal
studies: local application resulted in tumour-growth inhi-
bition and increased survival. However, this application
and dosage is not standard and cannot be recommended
widely due to potential risks of high dose or local applica-
tion. With ordinary VAE application, schedule and dos-
age, spectacular tumour remissions tend to be the
exception [20,36]. No tumour remission was observed
after application of rMLs. Remission in CIN cannot be dis-
tinguished from spontaneous remission rates, which are
frequent in this indication.
Apart from the discussed issues, the following validity
aspects have to be considered: An attrition rate above 10%
was present in 10 RCTs. In 5 of these RCTs [49-51,53],
patients were excluded before baseline assessment. Here
the patients were provisionally enrolled into the matching
and pairwise randomization procedure; subsequently
they were asked for informed consent, and were excluded
from the study if they declined, together with their
matched twin. Even though the risk of bias with this pro-
cedure is small, as the complete randomization unit
(patient pair) is excluded, the preferred conservative qual-
ity assessment in this review assessed these studies as not
having excluded a drop-out bias. Of the remaining 5 trials,
one had protocol violations in about 20% of patients as
discussed above [62], and one trial used an aggressive
chemotherapy that inevitably had to be halted in several
patients [63]. Three trials did not report details.
To reduce publication bias we also included unpublished
studies and conducted a thorough literature search with
extensive expert consultations. One unpublished RCT
(Lektinol in breast cancer by Schwiersch et al.) could not
be included as it was not released by the manufacturer.
Beyond this, we cannot rule out the existence of unpub-
lished and unknown RCTs, but we presume that no well-
conducted, large-size and valid trials escaped our atten-
tion. – Regarding preclinical studies achieving complete-
ness is nearly impossible. These experiments are usually
explorative, for instance when plant extracts are chemi-
cally analysed for active compounds or for cytotoxic
effects; in general only relevant results are published, but
not results of non-relevant or non-working models or
unstable chemicals. (Even in the reviewed experiments,
often not all but only the noteworthy results were pre-
sented in detail.)
Regarding funding, 27 of 28 controlled studies published
since 2000 reported their funding source: 11 studies
received funding from the pharmaceutical industry alone,
16 studies (all by Grossarth et al.) had both industry and
public funding. There was no difference of results depend-
ing on funding source.
Regarding non-RCTs, bias by self-selecting the treatment
is usually present in raw data. In particular, patients who
choose complementary treatments differ substantially
from patients not choosing them [70,146]. It is therefore
indispensable to conduct careful adjustment of baseline
imbalances or matching [147-149]. This has been done to
a varying degree in most studies except in one without any
adjustment [64], and in another which only adjusted for
the main outcome parameter but not for the other
reported results [69]. Without any adjustment, no conclu-
sions can be drawn regarding the applied treatment.
When conducted and analysed carefully, non-RCTs can
provide valuable information regarding external validity
and effectiveness, as they can investigate treatment effec-
tiveness under routine conditions without distortion by
the artificial and selective conditions of an RCT's experi-
mental situation [150].
In preclinical studies, VAE show substantial cytotoxic effects
in cells originating from breast and gynaecological cancer,
and display tumour-growth inhibition in animal studies.
Cytotoxicity, especially of the MLs (which bind on human
breast cancer cells [151]), may be the cause of tumour
reduction after local, intratumoural application of VAE. If
systemically applied, the cytotoxicity of the MLs is of less
relevance, as it is inhibited by serum glycoproteins [152]
and by anti-ML antibodies [153] which are produced after
a few weeks of VAE application. Therapeutic effects of the
MLs were inconsistent and not very impressive in the
reviewed experiments. However, in other tumour types,
MLs have also shown substantial growth-inhibiting effects
(e.g. [154-157]). Interestingly, in two experiments, the
application of VAE-activated macrophages in mice not
directly treated with VAE also showed tumour-growth
inhibiting effects, while the application of non-activated
macrophages had no effects [121]. Similarly in
melanoma, the application of VAE-activated splenocytes
inhibited metastasis [158,159].
In general, the predictive reliability of the preclinical stud-
ies for clinical application is fairly limited in most
instances. Clinical cancer disease is insufficiently mim-
icked by animal models, with major differences regarding
age, general condition, co-morbidity, invasiveness, metas-
tases, antigenicity, immune system etc. The results of pre-Journal of Experimental & Clinical Cancer Research 2009, 28:79 http://www.jeccr.com/content/28/1/79
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clinical screening, especially for treatment of solid
tumours, have therefore been largely disappointing. The
models currently regarded as best for cytotoxic substances
use patient-derived tumours that grow subcutaneously or
orthotopically in nude mice, as in several cases reviewed
here. Immuno-active substances may however still be
insufficiently assessed in immune-deficient animals, as
the main components of the immune system are missing
(nude mice, for instance, cannot generate mature T-lym-
phocytes). Nevertheless, these preclinical experiments can
provide important additional information for detecting
the possible anti-cancer effects of medicinal plants, their
active compounds, their mode of action and potential
risks [20,160-162].
Safety aspects
Mistletoe therapy was well tolerated in the reviewed stud-
ies. Mild flu-like symptoms and local reactions at the
injections sites are frequent, dose-dependent and self-lim-
ited. Allergic reactions can occur, and a few case reports of
anaphylactic reactions exist [163-166]. A phase I study,
conducted at the NCCAM/NCI, investigated safety, toxic-
ity and drug interactions between VAE and gemcitabine
[73] and reported good tolerability, with neither dose-
limiting toxicity of the VAE nor any effects on the plasma
concentration of gemcitabine [44]. Combination of VAE
with chemotherapy or radiotherapy did not negatively
influence remission rate in clinical and in animal studies
[56,63,118]. A higher prevalence of depression in VAE-
treated patients in one study was observed in raw data of
a self-selected population, without adjustment of baseline
imbalances. This difference can be ascribed to variations
in the patient population; for instance, they differed
markedly in the prevalence of hormone treatment. No
toxicity was observed in animal experiments.
Conclusion
Preclinical and clinical studies investigating the influence
of VAE and its isolated compounds on breast or gynaeco-
logical cancer suggest a benefit, with the strongest evi-
dence in relation to QoL and tolerability of conventional
anti-cancer treatments. Regarding survival, evidence is less
conclusive; most of the clinical studies had a very small
sample size (RCTs) and were embedded in the same large
cohort study; therefore an independent trial would be
needed. Tumour-growth inhibition has been insuffi-
ciently assessed in prospective clinical trials. Tumour
regression seems not to have been connected with regular
low-dose subcutaneous VAE treatment, but with high
dose and local application. The latter has not yet been
thoroughly assessed and is not generally recommended.
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